IL DONG PHARMACEUTICAL CO., LTD.
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Price
Change
Market cap
Products & technology
- Aronaminactive vitamin
- Flumarinantibiotic
- 큐란
- 라비에트
- 사미온
Regulatory approvals
data.go.kr432 Korean MFDS drug approvals · 1959–2026 / 17 Korean MFDS device approvals · 1998–2024
- MFDS drugAronamin Silver Multiplus Tab.2026-08-24Drug · OTC · Notification202602441
- MFDS drugFuraberinQ Tab.2026-03-25Drug · OTC · Notification202600835
- MFDS drugTwotops Tab. 20/2.5mg2026-02-26Drug · Prescription · Approval202600592
- MFDS drugAronamin C Plus Premium Tab.2026-02-12Drug · OTC · Notification202600394
- MFDS drugPITAQZET tablet 1/10mg(Pitavastatin calcium hydrate, Ezetimibe)2026-01-29Drug · Prescription · Approval202600265
- MFDS drugIldong Gongjindan2025-12-26Drug · OTC · Notification202503396
- MFDS drugTegoidtablet 50mg2025-11-20Drug · Prescription · Approval202503034
- MFDS drugTegoidtablet 25mg2025-11-20Drug · Prescription · Approval202503035
- MFDS drugCuninta Soft Cap.100mg2025-11-17Drug · Prescription · Approval202502962
- MFDS drugAronamin Gold Active Tab.2025-11-14Drug · OTC · Notification202502948
- MFDS drugAronamin Gold One Tablet2025-11-05Drug · OTC · Notification202502859
- MFDS drugCuninta Soft Cap.150mg2025-10-30Drug · Prescription · Approval202502814
Show 68 more
- MFDS drugPUREPASPEED Tab.2025-09-30Drug · OTC · Notification202502592
- MFDS drugEmpakhanlina tablet 10/5mg2025-09-26Drug · Prescription · Approval202502558
- MFDS drugEmpakhanlina tablet 25/5mg2025-09-26Drug · Prescription · Approval202502559
- MFDS drugEmpakhan duo tablet 5/850mg(Empagliflozin, Metformin Hydrochloride)2025-07-09Drug · Prescription · Approval202501726
- MFDS drugEmpakhan duo tablet 5/500mg(Empagliflozin, Metformin Hydrochloride)2025-07-09Drug · Prescription · Approval202501727
- MFDS drugEmpakhan duo tablet 5/1000mg(Empagliflozin, Metformin Hydrochloride)2025-07-09Drug · Prescription · Approval202501728
- MFDS drugEmpakhan duo tablet 12.5/1000mg(Empagliflozin, Metformin Hydrochloride)2025-07-09Drug · Prescription · Approval202501729
- MFDS drugEmpakhan duo tablet 12.5/850mg(Empagliflozin, Metformin Hydrochloride)2025-07-09Drug · Prescription · Approval202501730
- MFDS drugEmpakhan duo tablet 12.5/500mg(Empagliflozin, Metformin Hydrochloride)2025-07-09Drug · Prescription · Approval202501731
- MFDS drugLalaforce Sol.Revoked2025-05-12Drug · OTC · Notification202501145
- MFDS drugMagramin Liquid Double Action Solution2025-04-18Drug · OTC · Notification202500931
- MFDS drugCuninta tab. 150mg2025-04-18Drug · Prescription · Approval202500933
- MFDS drugCircuroxin Tab. 240mg(Ginkgo Leaf Dried Ext.)2025-04-18Drug · OTC · Notification202500930
- MFDS drugIldong Vipanthenol ointment(D-Panthenol)2025-04-14Drug · OTC · Notification202500870
- MFDS drugIldong Pyounsok Solution2025-04-09Drug · OTC · Notification202500895
- MFDS drugAtomibe tablet 10/5mg2025-02-28Drug · Prescription · Approval202500454
- MFDS drugMemansept Tab. 10/20mg2024-12-23Drug · Prescription · Approval202403045
- MFDS drugRoihitsubokocoin plaster2024-11-01Drug · OTC · Approval202402581
- MFDS drugConcen Vitapremium800 Tablet2024-07-02Drug · OTC · Notification202401612
- MFDS drugPUREPASEN600 Tab.(Diosmin)2024-06-19Drug · OTC · Notification202401475
- MFDSAlkali water producing equipment2024-02-13Product approval · Class 2수인 24-68 호
- MFDS drugExeraminacepremium tablet2024-01-10Drug · OTC · Notification202400077
- MFDS drugXARELIBAN Tablet 20mg(Rivaroxaban)2024-01-04Drug · Prescription · Approval202400030
- MFDS drugXareliban Tablet 15mg(rivaroxaban)2024-01-04Drug · Prescription · Approval202400031
- MFDS drugExeramin N tablets2023-08-16Drug · OTC · Notification202302440
- MFDS drugCarol Night Soft Capsule2022-12-26Drug · OTC · Notification202204634
- MFDS drugSitacombi Tab. 50/850mg2022-12-21Drug · Prescription · Approval202204594
- MFDS drugSitacombi Tab. 50/500mg2022-12-21Drug · Prescription · Approval202204595
- MFDS drugSitacombi Tab. 50/1000mg2022-12-21Drug · Prescription · Approval202204596
- MFDS drugIldong rivaroxaban tablet 15mg2022-06-02Drug · Prescription · Approval202202315
- MFDS drugIldong rivaroxaban tablet 10mg2022-06-02Drug · Prescription · Approval202202316
- MFDS drugIldong rivaroxaban tablet 20mg2022-06-02Drug · Prescription · Approval202202317
- MFDS drugREYVOW (lasmiditan hemisuccinate) tablet 50mg2022-05-11Drug · Prescription · Approval202201945
- MFDS drugREYVOW (lasmiditan hemisuccinate) tablet 100mg2022-05-11Drug · Prescription · Approval202201946
- MFDS drugSITACOMBI XR 50/500mg2022-05-09Drug · Prescription · Approval202201882
- MFDS drugSITACOMBI XR 50/1000mg2022-05-09Drug · Prescription · Approval202201883
- MFDS drugSITACOMBI XR 100/1000mg2022-05-09Drug · Prescription · Approval202201884
- MFDS drugXareliban Tablet 2.5mg(Rivaroxaban)Revoked2022-02-11Drug · Prescription · Approval202200678
- MFDS drugRabietduo Tablets 20/500mg2022-01-27Drug · Prescription · Approval202200474
- MFDS drugGLOTAPA tab. 10/100mgRevoked2022-01-04Drug · Prescription · Approval202200047
- MFDS drugRabietduo Tablets 10/500mg(Rabeprazole Sodium, Sodium Hydrogen Carbonate)2021-12-31Drug · Prescription · Approval202108207
- MFDS drugDAFORMET XR Tab. 10/500mg2021-12-23Drug · Prescription · Approval202108083
- MFDS drugDAFORMET XR Tab. 10/1000mg2021-12-23Drug · Prescription · Approval202108084
- MFDS drugAronamin Siver Active Tablet.2021-11-18Drug · OTC · Notification202107556
- MFDS drugARONAMIN EYE PLUS TABLETRevoked2021-11-16Drug · OTC · Notification202107496
- MFDS drugMAGRAMIN ACTIVE MAX Soft Capsule2021-10-27Drug · OTC · Notification202107155
- MFDS drugMAGRAMIN TRIPLE ACTION Tab.2021-10-26Drug · OTC · Notification202107129
- MFDS drugARONAMIN CARE THY Tab.2021-10-05Drug · OTC · Notification202106737
- MFDS drugPUREPAIN GEL2021-08-30Drug · OTC · Notification202106247
- MFDS drugEmpakhan tablet 10mg(empagliflozin)2021-07-29Drug · Prescription · Approval202105609
- MFDS drugEmpakhan tablet 25mg(empagliflozin)2021-07-29Drug · Prescription · Approval202105610
- MFDS drugAronamin Gold Premium tablet2021-03-04Drug · OTC · Notification202102039
- MFDS drugSitamono Tab. 100mg(Sitagliptin HCl Hydrate)2021-02-24Drug · Prescription · Approval202101851
- MFDS drugSitamono Tab. 50mg(Sitagliptin HCl Hydrate)Revoked2021-02-24Drug · Prescription · Approval202101849
- MFDS drugSitamono Tab. 25mg(Sitagliptin HCl Hydrate)Revoked2021-02-24Drug · Prescription · Approval202101850
- MFDS drugAtomibe tablet 10/40mg2021-02-18Drug · Prescription · Approval202101395
- MFDS drugAtomibe tablet 10/20mg2021-02-18Drug · Prescription · Approval202101396
- MFDS drugAtomib Tablet 10/10mg2021-02-18Drug · Prescription · Approval202101397
- MFDS drugIldong Kyungokgo2021-02-03Drug · OTC · Notification202101045
- MFDS drugCarol Night TabletRevoked2020-10-06Drug · OTC · Approval202006758
- MFDS drugCircatonin PR Tab. 2mg(melatonin)2020-09-22Drug · Prescription · Approval202006552
- MFDS drugDenQ Plus Tab.2020-06-08Drug · OTC · Notification202004270
- MFDS drugExeramin Pro Tab.2020-05-28Drug · OTC · Notification202003994
- MFDS drugDafor Tablet 10mg(dapagliflozin L-Proline)2020-05-22Drug · Prescription · Approval202003736
- MFDS drugIldong Esomeprazole Magnesium Trihydrate Tab. 40mgRevoked2020-05-22Drug · Prescription · Approval202003749
- MFDS drugIldong Esomeprazole Magnesium Trihydrate Tab. 20mgRevoked2020-05-22Drug · Prescription · Approval202003750
- MFDS drugCarol Kids A Syrup(Acetaminophen)2020-04-27Drug · OTC · Notification202003087
- MFDS drugCarol Kids Nose Syrup2020-04-22Drug · OTC · Notification202002848
Showing the 80 most recent of 449 records.
Clinical trials
data.go.kr96 MFDS clinical trial authorisations · 2012–2025 (Phase 1 49 · Bioequivalence 27 · Phase 3 17 · Phase 2/3 1 · Phase 4 1)
- BioequivalenceID625542025-09-01
2 trial sites
- Phase 1ID1105211562024-08-20
2 trial sites
- Phase 1일동닌테다닙정150밀리그램(닌테다닙에실산염)2024-05-21
1 trial site
- Phase 1ID1105211562023-09-05
2 trial sites
- Phase 1DW44212022-11-10
1 trial site
- Phase 3ID140092022-02-14
16 trial sites
- Phase 2/3S-2176222021-11-17
25 trial sites
- Phase 1ID140092021-11-17
2 trial sites
- Phase 1ID140092021-08-18
2 trial sites
- Bioequivalence유로탐스서방정(탐스로신염산염)2021-08-17
2 trial sites
- Bioequivalence유로탐스서방정(탐스로신염산염)2021-08-17
2 trial sites
- Bioequivalence아지탑스정250밀리그램(아지트로마이신수화물)2021-04-27
2 trial sites
Show 68 more
- Phase 1ID140092021-03-17
2 trial sites
- Bioequivalence쎄레원정200밀리그램2021-01-21
2 trial sites
- Bioequivalence자렐리반정2.5밀리그램(리바록사반)2020-08-07
2 trial sites
- Bioequivalence플루코팜캡슐(플루코나졸)2020-06-02
2 trial sites
- Bioequivalence플루코팜정150밀리그램2020-05-28
2 trial sites
- Phase 1LB803802020-02-03
1 trial site
- Phase 3일동COL-144정2019-12-23
13 trial sites
- Phase 1ID140092019-12-02
1 trial site
- Bioequivalence자렐리반정2.5밀리그램(리바록사반)2019-10-04
2 trial sites
- Phase 3ID1201정2019-08-02
- Bioequivalence아토미브정10/40밀리그램2019-07-09
2 trial sites
- Phase 1일동COL-144정2019-06-27
2 trial sites
- BioequivalenceIDFV750mg2019-05-09
2 trial sites
- Bioequivalence일동팜비어정250밀리그램(팜시클로비르)(가칭)2019-01-25
1 trial site
- Phase 4LB803802018-11-21
1 trial site
- Bioequivalence일동리바록사반정20밀리그램2017-09-01
2 trial sites
- Bioequivalence몬테루칸속붕해정5밀리그램(몬테루카스트나트륨)2016-10-06
2 trial sites
- Phase 1TAH정2016-07-25
1 trial site
- Phase 1IDCCG7322016-07-05
1 trial site
- Phase 3ML정2016-05-25
- Phase 1TAR정2016-04-28
1 trial site
- Phase 1TAR정2016-01-28
1 trial site
- Phase 1IDCCG7322016-01-08
1 trial site
- Phase 3드롭탑정(RE정)2016-01-05
20 trial sites
- Phase 3DoubleT정2015-12-24
17 trial sites
- Phase 1ID-CV10/160밀리그램2015-11-06
1 trial site
- Phase 3모티렙5/100밀리그램2015-11-05
26 trial sites
- Phase 1TAH정2015-09-14
1 trial site
- Phase 3TS정2015-09-07
28 trial sites
- Phase 1RVD정2015-08-13
1 trial site
- Bioequivalence일동히드로클로로티아지드정25밀리그램2015-08-03
2 trial sites
- Phase 3TAR정2015-07-28
19 trial sites
- Phase 1LB803802015-06-11
1 trial site
- Bioequivalence투탑스정80/10밀리그램2015-03-26
2 trial sites
- Phase 3TAH정2015-03-10
28 trial sites
- Phase 1ID-CV10/160밀리그램2015-01-13
1 trial site
- Phase 1APD791캡슐2015-01-06
1 trial site
- Phase 3LB803802014-12-04
24 trial sites
- Bioequivalence리피스톱정40밀리그램(아토르바스타틴칼슘삼수화물)2014-10-15
2 trial sites
- Phase 2ID1201정2014-10-06
26 trial sites
- Phase 1ML정2014-10-06
1 trial site
- Phase 3RF정2014-10-01
40 trial sites
- Phase 1드롭탑정(RE정)2014-09-04
1 trial site
- Phase 1LB803802014-09-02
1 trial site
- Phase 1TS정2014-08-05
1 trial site
- Bioequivalence스펙사정250밀리그램(게피티니브)2014-07-21
2 trial sites
- Bioequivalence일동타다라필정20밀리그램(타다라필)2014-05-21
2 trial sites
- Bioequivalence라펜타정60밀리그램(라록시펜염산염)2014-05-21
2 trial sites
- Phase 3드롭탑정(RE정)2014-05-20
28 trial sites
- Phase 3ML정2014-03-10
12 trial sites
- Phase 1IDF-11774 HCl 캡슐2014-02-21
1 trial site
- Phase 1ID-CV10/160밀리그램2014-02-06
1 trial site
- Phase 1IDV-12002 캡슐 35mg, 280mg2014-01-17
- Phase 1텔로탄정2014-01-16
1 trial site
- Phase 1모티렙5/100밀리그램2014-01-08
1 trial site
- Phase 1TAR정2013-12-05
1 trial site
- Bioequivalence유로케어정10밀리그램(솔리페나신숙신산염)2013-11-08
2 trial sites
- Phase 1APD791캡슐2013-10-25
1 trial site
- Phase 1TAH정2013-10-16
1 trial site
- Phase 1LoxoR 68.1/100밀리그램2013-10-14
1 trial site
- Phase 1DoubleT정2013-09-03
1 trial site
- Phase 3ID-CV10/160밀리그램2013-08-26
24 trial sites
- Bioequivalence바이큐어정1밀리그램(엔테카비르)2013-08-07
2 trial sites
- Phase 3LB803802013-07-26
22 trial sites
- Phase 1RF정2013-06-19
1 trial site
- Bioequivalence펜토웰서방정400mg(펜톡시필린)2013-06-18
2 trial sites
- Bioequivalence쎄레원캡슐200mg(세레콕시브)2013-05-27
2 trial sites
- Phase 1글리멜스타정4/20밀리그램2013-05-16
1 trial site
Showing the 80 most recent of 96 records.
R&D and key agreements
Source: DART corporate disclosure위식도역류질환·대사성질환·호흡기질환 치료제 파이프라인 · 위식도 역류질환, 대사성 질환, 호흡기 질환 · Spending about 6.54% of revenue (KRW 36.591 billion) on R&D to develop treatments in these areas.
Companies approved for the same productsPharma & CDMO
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Alpha AI, founded in 1995 and KOSDAQ-listed in 2000, manufactures biocompatible metal implants and surgical instruments.
GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.
KOSPI-listed pharmaceutical company behind the combination drugs Amosartan (hypertension) and Rosuzet (dyslipidemia).
Sinsin Pharmaceutical sells medicated patches and OTC medicines through direct deals with over 13,000 pharmacies nationwide.
Wonbiogen Co.,Ltd., established September 2018, listed on KOSDAQ in December 2018, manufactures wound dressings and moist wound dressings.
Founded and listed on the KOSDAQ in 2016, BNC Korea is a biohealthcare company specializing in HA fillers, botulinum toxin, and dermo-cosmetics.
Holds manufacturing approvals for 42 point-of-care diagnostic reagents and devices in the IVD market.
Founded in 1996 and listed on KOSDAQ in 1999, ChoA Pharmaceutical is an OTC-focused drugmaker exporting to 23 countries worldwide.
Founded in 1980, Korean Drug produces the cold medicine Haben and the dementia drug Neuromed, along with other CNS disease treatments.
MITECH CO.,LTD., founded in 1991 and listed on KOSDAQ in 2018, makes non-vascular stents and distributes Fujifilm endoscopy equipment.
Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.
Founded in 1966, KOSPI-listed PharmGen Science makes GI and cardiovascular prescription drugs plus health foods and beauty products.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition